Suven Life Sciences Dirección

Dirección controles de criterios 2/4

El CEO de Suven Life Sciences es Venkat Jasti, nombrado en Oct 2004, tiene una permanencia de 20.08 años. posee directamente un 0.001% de las acciones de la empresa, con un valor de ₹260.23K. La antigüedad media del equipo directivo y de la junta directiva es de 14.2 años y 10.5 años, respectivamente.

Información clave

Venkat Jasti

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	20.1yrs
Participación del CEO	0.001%
Permanencia media de la dirección	14.2yrs
Promedio de permanencia en la Junta Directiva	10.5yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Venkat Jasti en comparación con los beneficios de Suven Life Sciences?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-₹1b
Jun 30 2024	n/a	n/a	-₹1b
Mar 31 2024	n/a	n/a	-₹1b
Dec 31 2023	n/a	n/a	-₹1b
Sep 30 2023	n/a	n/a	-₹1b
Jun 30 2023	n/a	n/a	-₹1b
Mar 31 2023	n/a	n/a	-₹1b
Dec 31 2022	n/a	n/a	-₹1b
Sep 30 2022	n/a	n/a	-₹940m
Jun 30 2022	n/a	n/a	-₹991m
Mar 31 2022	n/a	n/a	-₹1b
Dec 31 2021	n/a	n/a	-₹1b
Sep 30 2021	n/a	n/a	-₹1b
Jun 30 2021	n/a	n/a	-₹1b
Mar 31 2021	n/a	n/a	-₹722m
Dec 31 2020	n/a	n/a	-₹761m
Sep 30 2020	n/a	n/a	-₹745m
Jun 30 2020	n/a	n/a	-₹787m
Mar 31 2020	n/a	n/a	-₹942m
Dec 31 2019	n/a	n/a	₹28m
Sep 30 2019	n/a	n/a	₹1b
Jun 30 2019	n/a	n/a	₹871m
Mar 31 2019	₹58m	₹29m	-₹239m
Mar 31 2018	₹47m	₹25m	₹1b

Compensación vs. Mercado: Datos insuficientes para determinar si la compensación total de Venkat es razonable en comparación con empresas de tamaño similar en el mercado Indian.

Compensación vs. Ingresos: La compensación de Venkat ha aumentado mientras la empresa no es rentable.

CEO

Venkat Jasti (75 yo)

20.1yrs

Permanencia

Mr. Venkateswarlu Jasti, also known as Venkat, M.Pharm. M.S., has been the Managing Director and Executive Chairman of the Board of Suven Life Sciences Limited since November 01, 2024. He is Member of Advi...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Venkateswarlu Jasti	CEO, MD & Executive Chairman	20.1yrs	sin datos	0.0010% ₹ 266.1k
Sudharani Jasti	Whole-Time Director	35.7yrs	₹9.99m	0.70% ₹ 184.6m
M. Kumar	Chief Financial Officer	4.8yrs	sin datos	sin datos
Kundan Jha	Company Secretary & Compliance Officer	less than a year	sin datos	sin datos
Kalyani Jasti	President of US Operations	14.2yrs	sin datos	0.00046% ₹ 121.2k

14.2yrs

Permanencia media

70yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 530239 es experimentado (14.2 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Venkateswarlu Jasti	CEO, MD & Executive Chairman	35.7yrs	sin datos	0.0010% ₹ 266.1k
Sudharani Jasti	Whole-Time Director	35.7yrs	₹9.99m	0.70% ₹ 184.6m
Seyed Hasnain	Non-Independent & Non-Executive Director	14.6yrs	₹200.00k	sin datos
Santanu Mukherjee	Independent Non-Executive Director	6.5yrs	₹250.00k	sin datos
Jasthi Ananthasai Padmaja	Independent Non-Executive Director	6yrs	₹110.00k	sin datos
Vajja Rao	Independent Director	less than a year	sin datos	sin datos

10.5yrs

Permanencia media

70yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de 530239 son experimentados ( 10.5 años antigüedad media).

Suven Life Sciences Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Suven Pharma Announces Board Changes

Suven Life Sciences Limited Announces Step Down of Vaidheesh Annaswamy as Executive Chairperson and Director

Suven Life Sciences Limited, Annual General Meeting, Aug 02, 2024

Suven Life Sciences Limited Approves the Retirement of Gopalakrishna Muddusetty as Non-Executive Independent Director, Effective March 31, 2024

Suven Pharma Appoints Sudhir Kumar Singh as CEO

Suven Life Sciences Limited, Annual General Meeting, Aug 05, 2023

Recent updates

New major risk - Financial position

Second quarter 2025 earnings released: ₹2.27 loss per share (vs ₹0.58 loss in 2Q 2024)

Suven Life Sciences Limited to Report Q2, 2025 Results on Nov 12, 2024

Suven Pharma Announces Board Changes

Suven Life Sciences Limited Announces Step Down of Vaidheesh Annaswamy as Executive Chairperson and Director

Suven Life Sciences Announces Positive Topline Results from Phase-2A Proof-Of-Concept Signal Detection Open Label Study of Ropanicant (Suvn-911) for the Treatment of Moderate to Severe Major Depressive Disorder

Suven Life Sciences Announces FDA Acceptance of Investigational New Drug (IND) and Grant of Study May Proceed Letter to Initiate Phase-1 Clinical Trial of SUVN-I6107

New minor risk - Share price stability

First quarter 2025 earnings released: ₹1.29 loss per share (vs ₹1.10 loss in 1Q 2024)

Suven Life Sciences Limited to Report Q1, 2025 Results on Aug 05, 2024

Full year 2024 earnings released: ₹4.82 loss per share (vs ₹6.63 loss in FY 2023)

Suven Life Sciences Limited, Annual General Meeting, Aug 02, 2024

Full year 2024 earnings released: ₹4.82 loss per share (vs ₹6.63 loss in FY 2023)

Third quarter 2024 earnings released: ₹1.92 loss per share (vs ₹2.90 loss in 3Q 2023)

Suven Life Sciences Limited Approves the Retirement of Gopalakrishna Muddusetty as Non-Executive Independent Director, Effective March 31, 2024

Suven Life Sciences Limited to Report Q3, 2024 Results on Jan 30, 2024

New major risk - Share price stability

Suven Life Sciences Limited to Report Q4, 2024 Results on May 15, 2024

Second quarter 2024 earnings released: ₹0.58 loss per share (vs ₹1.59 loss in 2Q 2023)

New minor risk - Share price stability

Suven Life Sciences Limited to Report Q2, 2024 Results on Nov 04, 2023

Suven Pharma Appoints Sudhir Kumar Singh as CEO

Suven Life Sciences Limited to Report Q1, 2024 Results on Aug 08, 2023

Full year 2023 earnings released: ₹6.63 loss per share (vs ₹9.05 loss in FY 2022)

Suven Life Sciences Completes Enrollment of Patients to the Phase-2, Proof of Concept Clinical Study of Samelisant (SUVN-G3031) for the Treatment of Narcolepsy with or Without Cataplexy in USA and Canada

Suven Life Sciences Limited, Annual General Meeting, Aug 05, 2023

Full year 2023 earnings released: ₹6.63 loss per share (vs ₹9.57 loss in FY 2022)

Third quarter 2023 earnings released: ₹2.90 loss per share (vs ₹2.65 loss in 3Q 2022)

Suven Life Sciences Limited to Report Q3, 2023 Results on Feb 02, 2023

Suven Life Sciences Limited Announces the Randomization of First Patient in the Phase-3 Global Clinical Trial of Masupirdine for the Treatment of Agitation in Patients with Dementia of the Alzheimer's Type

Price target decreased to ₹306

Insufficient new directors

Second quarter 2023 earnings released

Suven Life Sciences Limited to Report Q2, 2023 Results on Nov 08, 2022

Suven Life Sciences Limited Declares Special Dividend for the Financial Year 2022-23, Payable on and from September 20, 2022

Suven Life Sciences Limited to Report Q1, 2023 Results on Jul 26, 2022

Full year 2022 earnings released: ₹9.57 loss per share (vs ₹5.67 loss in FY 2021)

Suven Life Sciences Limited Declares One-Time Special Dividend for the Financial Year 2021-22, Payable on and from 25 May, 2022

Full year 2022 earnings released: ₹9.57 loss per share (vs ₹5.67 loss in FY 2021)

Suven Life Sciences Limited, Annual General Meeting, Aug 04, 2022

Suven Life Sciences Limited to Report Q4, 2022 Results on May 07, 2022

Price target decreased to ₹306

Insufficient new directors

Suven Life Sciences Limited Declares Interim Dividend, Payable on and from 22 February 2022

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Insufficient new directors

Insufficient new directors

Second quarter 2022 earnings released: ₹2.22 loss per share (vs ₹1.23 loss in 2Q 2021)

Price target decreased to ₹306

Full year 2021 earnings released: ₹5.67 loss per share (vs ₹7.40 loss in FY 2020)

Price target increased to ₹472

Full year 2021 earnings released: ₹5.67 loss per share (vs ₹7.40 loss in FY 2020)

Suven Life Sciences Limited announced that it has received INR 369.10425 million in funding from Jasti Family Trust

Independent Non-Executive Director has left the company

Third quarter 2021 earnings released: ₹1.92 loss per share (vs ₹1.79 loss in 3Q 2020)

Suven Life Sciences Limited to Report Q3, 2021 Results on Jan 28, 2021

New 90-day high: ₹57.90

First half earnings released

New 90-day high: ₹56.45

Insider recently bought ₹1.0m worth of stock

New 90-day high - ₹54.50

Suven Life Sciences Limited to Report Q1, 2021 Results on Aug 17, 2020

First quarter earnings released

New 90-day high - ₹48.55

Suven Life Sciences Limited to Report Q1, 2021 Results on Aug 11, 2020

Price target raised to ₹537

Suven Life Sciences Limited(BSE:530239) dropped from S&P Global BMI Index

Análisis de compensación del CEO

CEO